ML
EPZM

McAdam LLC’s Epizyme, Inc EPZM Stock Holding History

McAdam LLC’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-430
Closed -$4K – 680
2018
Q3 		$4K Buy
+430
New +$4.91K ﹤0.01% 453

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

McAdam LLC's EPZM Position: Q4 2018 in Review

McAdam LLC sold out of Epizyme, Inc (EPZM) in Q4 2018, closing a stake of 430 shares — an estimated $4K sold.

McAdam LLC first reported a position in EPZM in Q3 2018 and held it in 1 quarter. The position peaked at $4K in Q3 2018. 105 funds tracked by Wall St. Rank hold EPZM as of Q4 2018.

  • McAdam LLC reported no remaining Epizyme, Inc position as of Q4 2018 after selling out during the quarter.
  • McAdam LLC sold 430 Epizyme, Inc shares in Q4 2018, an estimated $4K.
  • McAdam LLC first reported a position in Epizyme, Inc in Q3 2018 and held it in 1 quarter.
  • McAdam LLC's Epizyme, Inc position peaked at $4K in Q3 2018.
  • 105 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.